. 2017 Feb 28;11:353–362. doi: 10.2147/PPA.S121838

Table 4.

Results of mixed effects logistic regression model for DCE in individuals with psoriasis reporting treatment preferences, stratified by subgroup

Treatment attribute	DLQI ≤10, n=166, OR (95% CI)	DLQI >10, n=126, OR (95% CI)	Biologic therapy experience, n=75, OR (95% CI)	Biologic therapy naïve, n=217, OR (95% CI)
BSA (per palm area)	0.90 (0.88–0.93)^a	0.97 (0.95–1.00)	0.97 (0.94–1.00)	0.90 (0.88–0.92)^a
Increased risk of diarrhea or nausea (per 5% increase)	0.84 (0.79–0.90)^a	0.88 (0.82–0.94)^a	1.01 (0.93–1.09)	0.79 (0.75–0.85)^a
Increased risk of melanoma or nonmelanoma skin cancer (per 5% increased 10-year risk)	0.43 (0.35–0.53)^a	0.45 (0.36–0.56)^a	0.57 (0.44–0.74)^a	0.38 (0.32–0.46)^a
Increased risk of tuberculosis (per 5% increased 10-year risk)	0.73 (0.66–0.80)^a	0.75 (0.67–0.83)^a	0.85 (0.75–0.97)^a	0.66 (0.60–0.72)^a
Increased risk of serious infection (per 5% increased 10-year risk)	0.70 (0.67–0.72)^a	0.79 (0.76–0.81)^a	0.87 (0.85–0.90)^a	0.70 (0.68–0.72)^a
Twice-daily tablet (relative to once-weekly tablet)	0.74 (0.60–0.91)^a	0.75 (0.61–0.93)^a	0.79 (0.61–1.02)	0.71 (0.59–0.85)^a
Weekly injection (relative to once-weekly tablet)	0.48 (0.39–0.61)^a	0.72 (0.57–0.90)^a	0.84 (0.63–1.11)	0.43 (0.35–0.53)^a
Fortnightly injection (relative to once-weekly tablet)	0.49 (0.40–0.60)^a	0.86 (0.70–1.06)	0.78 (0.60–1.02)	0.57 (0.48–0.69)^a

Note:

Attributes significant at the <5% level.

Abbreviations: BSA, body surface area; CI, confidence interval; DCE, discrete choice experiment; DLQI, Dermatology Life Quality Index; OR, odds ratio.